CLET is a published treatment for the management of corneal failure due to extensive LSCD. Due to our previous studies on this novel treatment, the regulatory agency of Spain "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" authorized our institution (IOBA-University of Valladolid) to perform this kind of therapy (CLET) in a case-by-case base following the Special Situation Medicines Policy Procedure in Spain. Upon approval of the permanent authorization patients will be included as specified by AEMPS.The objective of this study is to perform a protocolized treatment and follow up so that results can be reported to the scientific community.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Points of improvement in the Single Item Dry Eye Questionnaire (SIDEQ)
Timeframe: 6 months
Points of improvement about the Ocular Surface Disease Index (OSDI)
Timeframe: 6 months
Points of improvement in the National Eye Institute 25-item Visual Function Questionnaire (NEI-VFQ25)
Timeframe: 6 months
Points of improvement in the Change in Dry Eye Symptoms Questionnaire (CDES-Q)
Timeframe: 6 months
Percentage of improvement in corneal conjunctivalization
Timeframe: 6 months
Complete absence of persistent epithelial defects
Timeframe: 6 months